SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and P ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 p.m. PT. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, ...

Investors might want to bet on CytomX Therapeutics (CTMX) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the s ...

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 - - Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships during 2025 - - Revised focus and associated cost and headcount reductions expected to extend cash runway into the second quarter of 2026 - - Company to present at 43rd ...

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 - - Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships during 2025 - - Revised focus and associated cost and headcount reductions expected to extend cash runway into the second quarter of 2026 - - Company to present at 43rd ...

The price trend for CytomX Therapeutics (CTMX) has been bearish lately and the stock has lost 5.9% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor th ...

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www ...

CytomX Therapeutics (CTMX) has been beaten down lately with too much selling pressure. While the stock has lost 25.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillat ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Chris Ogden - CFO Sean A. McCarthy - Chairman and CEO Conference Call Participants Joseph Catanzaro - Piper Sandler Liang Cheng - Jefferies Etzer Darout - BMO Capital Markets Anupam Rama - J.P. Morgan Unidentified Analyst - H.C. Wainwright Operator Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics Third Quarter 2024 Financial Results Call. Please be advi ...

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 143.75%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.07 per share when it actually produced a loss of $0.08, delivering a surprise of -14.29%.Over the la ...